Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical
company focused on precision diagnostic radiopharmaceuticals, today
announced that the Company will report its financial results for the
second quarter 2014, on Wednesday, August 6, 2014 before the market
opens. The announcement will be followed by a conference call with the
investment community, at 8:30 a.m. EDT.
Investors and the public are invited to access the live audio webcast
through the link below. Participants who would like to ask questions
during the question and answer session must participate by telephone
also. Participants are encouraged to log-in and/or dial-in fifteen
minutes before the conference call begins. The webcast replay is
expected to be available on our investor website, http://ir.navidea.com,
approximately two to four hours after the live event.
A webcast replay will be available on the Investor Relations
section of our website at http://ir.navidea.com
for 30 days.
About Navidea Biopharmaceuticals Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical
company focused on the development and commercialization of precision
diagnostics and radiopharmaceutical agents. Navidea is developing
multiple precision diagnostic products and platforms including
Manocept™, NAV4694, NAV5001, and NAV1800 (RIGScan™), to help identify
the sites and pathways of undetected disease and enable better
diagnostic accuracy, clinical decision-making and, ultimately, patient
(technetium TC 99m tilmanocept) Injection, Navidea's first commercial
product from the Manocept platform, was approved by the FDA in March
2013. Navidea's strategy is to deliver superior growth and shareholder
return by bringing to market novel radiopharmaceutical agents and
advancing the Company's pipeline through selective acquisitions, global
partnering and commercialization efforts. For more information, please
[ Back To NFVZone's Homepage ]